NCT00624845已完成2 期
Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 8
- 主要终点
- The primary efficacy endpoint is the mean VAS at 24 hours postoperatively.
研究概览
简要总结
The purpose of this study is to assess the benefit of OMS103HP for Injection (OMS103HP) compared with vehicle irrigation solution for prevention of pain and pain relief in subjects undergoing meniscectomy. The pain relief is assessed based on Visual Analog Scale (VAS) Pain Scores in the immediate 24-hour postoperative period and for seven days postoperatively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has voluntarily signed informed consent form, including HIPAA Authorization.
- •Subject is ≥ 18 and ≤ 75 years of age.
- •Subject is in good general health with a traumatic or degenerative meniscal cartilage injury (full tear) that occurred at least 14 days prior to the day of arthroscopic surgery.
- •Subject is undergoing unilateral meniscectomy.
- •Subject's physical examination is within normal limits or examination is clinically nonsignificant as determined by the Investigator, and subject is in good general health.
- •Subject's laboratory evaluations are within normal limits or evaluations are clinically nonsignificant as determined by the Investigator.
- •Subject, if female and of childbearing potential (i.e., not surgically sterilized or post-menopausal greater than one year) agrees to use an effective method of birth control for the duration of her study involvement.
- •Subject is at minimal risk from anesthesia and is classified according to the American Society of Anesthesiologists Physical Status Classification as either PS-1 (a normal healthy patient) or PS-2 (a patient with mild systemic disease that results in no functional limitation). See Appendix VI.
- •Subject agrees to refrain from taking the excluded medications listed in Exclusion Criteria through postoperative Day 7 (except for authorized analgesic medications) unless written permission has been granted by Omeros.
- •Subject is able to be proficient in the use of the ePRO device (documented at the site).
排除标准
- •Subject with significant arthritis (>2 on the Kellgren-Lawrence Scale).
- •Subject with a history of reactive synovial disease.
- •Subject with current, or history of, complex regional pain syndrome (Type I, i.e., reflex sympathetic dystrophy, or Type II, i.e., causalgia), chronic pain, attendance at a chronic pain clinic, or neurologic disorder associated with any sensory deficit of the lower extremities.
- •Subject with current, or history of fibromyalgia.
- •Subject taking ANY ANALGESIC (including salicylates, opioids, propoxyphene, etc.) on the day of surgery from 12:00 A.M. until after the procedure, except for medications authorized by the Investigator or delegated staff.
- •Subject taking any of the following medications within the stated time frames prior to the day of surgery.
- •Amitriptyline within 30 days
- •More than two doses of sumatriptan, (or any other drug in the triptan class), ondansetron, or other prescription serotonergic or histaminic drug within 14 days
- •More than two doses of any oral, parenteral, or intravenous steroids (e.g., dexamethasone for antiemetic prophylaxis) within 3 months
- •More than two doses of oxymetazoline or other nasal decongestant/cold/cough/allergy medication (including loratadine) within 7 days
- •More than two doses of ketoprofen or other NSAID (including COX-2 inhibitors) within 7 days (except for piroxicam, as indicated below)
- •Subject who has taken more than two doses of opioid pain medication within the prior seven days of surgery or chronic use of opioid pain medications for greater than 6 weeks within the prior year
- •More than two doses of piroxicam within 14 days
- •Subject with a history of intra-articular corticosteroid injection in the operative knee within the two months prior to the meniscectomy
- •Subject expected to undergo any of the following procedures concurrent with meniscectomy:
- •Arthroscopic patellar tendon debridement
- •Patellar alignment
- •Lateral or retinacular release
- •Excision synovectomy (minor synovectomy to improve arthroscopic visualization is acceptable)
- •Concurrent ligamentous procedure
- •Microfracture
- •Abrasion arthroplasty
- •Chondral transplantation
- •Use of more than three portals
- •Subject with allergies to any of the individual ingredients in OMS103HP, to related compounds (e.g., other NSAIDs or tricyclic antidepressants), or to opioid analgesics.
- •Subject who is pregnant or breast-feeding.
- •Subject with Worker's Compensation claim(s) under dispute or mediation.
- •Subject with history of drug or alcohol abuse.
- •Subject who has taken or used an investigational drug or device within 30 days prior to the day of surgery.
- •Subject with a history or presence of systemic disease (renal, hepatic, psychiatric, etc.), which in the opinion of the Medical Monitor and the Principal Investigator, may place the subject's health at risk by participation in the study.
- •Subject who is expected to receive a regional block for analgesia for this procedure.
- •Subject who is considered by the Investigator for any reason to be an unsuitable candidate for receipt of an investigational drug.
研究组 & 干预措施
Drug
Experimental
干预措施: OMS103HP (Drug)
Vehicle
Placebo Comparator
干预措施: Vehicle (Drug)
结局指标
主要结局
The primary efficacy endpoint is the mean VAS at 24 hours postoperatively.
时间窗: 24 hours
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic MeniscectomyMeniscal TearNCT01406561Omeros Corporation344
已完成
1 期
Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.Cataract ExtractionNCT00721695Omeros Corporation60
撤回
不适用
A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity Disorder (ADHD)NCT00323700University of British Columbia200
招募中
2 期
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisPsoriasisNCT06077331Hansoh BioMedical R&D Company120
招募中
2 期
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic ArthritisPsoriatic ArthritisNCT06176508Hansoh BioMedical R&D Company160